

Table 2

| <b>Author</b>                          | <b>Title</b>                                                                                                                  |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| AHCDO (2006)                           | Evidence-based clinical practice guidelines for the use of recombinant and plasma derived FVIII and FIX products              |
| AHCDO (2010)                           | Guideline for the management of patients with haemophilia undergoing surgical procedures                                      |
| Anderson <i>et al.</i> (2013)          | Guidance on the dental management of patients with haemophilia and congenital bleeding disorders                              |
| Bertamino <i>et al.</i> (2017)         | Haemophilia in the pediatric age                                                                                              |
| Blanchette <i>et al.</i> (2014)        | Definitions in hemophilia: communication from the SSC of the ISTH                                                             |
| Chalmers <i>et al.</i> (2011)          | Guideline on the management of haemophilia in the fetus and neonate                                                           |
| Collins <i>et al.</i> (2013)           | Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)                             |
| Giangrande <i>et al.</i> (2017)        | Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates                     |
| Mingot-Castellano <i>et al.</i> (2015) | Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors     |
| NHF (2015)                             | MASAC recommendation on administration of inhibitor bypassing agents in the home for patients with haemophilia and inhibitors |
| NHF (2015)                             | MASAC recommendations regarding physical therapy guidelines in patients with bleeding disorders                               |
| NHF (2016)                             | MASAC recommendations regarding doses of clotting factor concentrate in the home                                              |
| NHF (2016)                             | MASAC recommendations concerning products licensed for the treatment of haemophilia and other bleeding disorders              |
| NHF (2016)                             | MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding)       |
| NHF (2016)                             | NHF-McMaster Guideline on Care Models for Haemophilia Management                                                              |
| NHS (2013)                             | Haemophilia service guideline: management of bleeding episodes in adults with haemophilia                                     |
| Pipe and Kessler (2016)                | Evidence-based guidelines support integrated disease management as the optimal model of haemophilia care                      |
| Santagostino <i>et al.</i> (2014)      | Switching treatments in haemophilia: is there a risk of inhibitor development?                                                |
| UKHCDO (2008)                          | Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders       |
| UKHCDO (2009)                          | Emergency and out of hours care for patients with bleeding disorders – standards of care for assessment and treatment         |

|               |                                                                                                                                                                                                                                                   |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| UKHCDO (2010) | A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A |
| UKHCDO (2016) | The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO                                                                                                                                  |
| UKHCDO (2017) | Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia                                                                                                                                                          |
| UKHCDO (2017) | Management of inherited bleeding disorders in pregnancy                                                                                                                                                                                           |
| UKHCDO (2017) | UKHCDO protocol for first line immune tolerance induction for children with severe haemophilia A: A protocol from the UKHCDO Inhibitor and Paediatric Working Parties                                                                             |
| WFH (2012)    | Guidelines for the management of haemophilia                                                                                                                                                                                                      |
| WFH (2013)    | Updates to the guidelines for the management of haemophilia – April 2013                                                                                                                                                                          |